Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) : study protocol

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F11%3A00102106" target="_blank" >RIV/00843989:_____/11:00102106 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/11:A12014HS

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.155.2011.004143" target="_blank" >http://dx.doi.org/10.5507/bp.155.2011.004143</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.155.2011.004143" target="_blank" >10.5507/bp.155.2011.004143</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) : study protocol

Popis výsledku v původním jazyce

Background. There is currently limited data on which drug should be used to improve blood pressure control in patients with resistant hypertension. Recent observational trials reported spironolactone as having good effects. This study is designed to assess the effect of the addition of 25 mg of spironolactone on blood pressure (BP) in patients with resistant arterial hypertension. Methods. Patients with office systolic BP > 140 mmHg or diastolic BP > 90 mmHg despite treatment with at least 3 antihypertensive drugs including a diuretic, are enrolled in this double-blind, placebo-controlled, multicentre trial. Patients are randomly assigned to receive spironolactone or a placebo at a ratio of 1:1 by the method of simple randomisation. Our primary endpoints are to show a statistically significant difference in the fall of mean day-time systolic and diastolic BP by ambulatory blood pressure monitoring (ABPM), between the spironolactone and placebo groups, after 8 weeks of treatment. Second

Název v anglickém jazyce

Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) : study protocol

Popis výsledku anglicky

Background. There is currently limited data on which drug should be used to improve blood pressure control in patients with resistant hypertension. Recent observational trials reported spironolactone as having good effects. This study is designed to assess the effect of the addition of 25 mg of spironolactone on blood pressure (BP) in patients with resistant arterial hypertension. Methods. Patients with office systolic BP > 140 mmHg or diastolic BP > 90 mmHg despite treatment with at least 3 antihypertensive drugs including a diuretic, are enrolled in this double-blind, placebo-controlled, multicentre trial. Patients are randomly assigned to receive spironolactone or a placebo at a ratio of 1:1 by the method of simple randomisation. Our primary endpoints are to show a statistically significant difference in the fall of mean day-time systolic and diastolic BP by ambulatory blood pressure monitoring (ABPM), between the spironolactone and placebo groups, after 8 weeks of treatment. Second

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical papers

ISSN

1213-8118

e-ISSN

—

Svazek periodika

Vol.155

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

143-148

Kód UT WoS článku

000294040300006

EID výsledku v databázi Scopus

—